InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205)

Catalog No.

VVV00304

Species reactivity

SARS-CoV-2(2019-nCoV)

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

Spike

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P0DTC2

Applications

ELISA, Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0205

Comprehensive analysis of SARS-CoV-2 Spike evolution: epitope classification and immune escape prediction., PMID:40510757

Conformational Landscaping and Dynamic Mutational Profiling of Binding Interactions and Immune Escape for Broadly Neutralizing Class I Antibodies with SARS-CoV-2 Spike Protein: Distributed Binding Hotspot Networks Underlie Mechanism of Viral Resistance Against Existing Variants., PMID:40510568

Reduced SARS-CoV-2 vaccine-specific antibody response associated with high clozapine doses in schizophrenia spectrum disorders., PMID:40502531

Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates., PMID:40498855

Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection., PMID:40498720

Long COVID-19 autoantibodies and their potential effect on fertility., PMID:40496870

Development of a peptide-based vaccine using a T cell epitope derived from SARS-CoV-2., PMID:40487437

Nanobody-based fluorescent immunoassay for SARS-CoV-2 spike detection via site-specific microbial transglutaminase labeling., PMID:40483875

Single-particle quantification of SARS-CoV-2 virus-like particles using flow virometry., PMID:40483334

Immune age is correlated with decreased TCR clonal diversity and antibody response to SARS-CoV-2., PMID:40481111

Serum Levels of IL-21 and IL-27 Do not Reflect differential Avidity of Anti-SARS-CoV-2 IgG Antibodies in Symptomatic and Asymptomatic COVID-19 Patients., PMID:40471646

Fc-effector functional antibody assays for SARS-CoV-2 variants of concern., PMID:40463385

Scalable Production of Recombinant Vesicular Stomatitis Virus Pseudoparticles Using HEK293 Suspension Cultures., PMID:40462709

Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study., PMID:40462400

SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023., PMID:40462062

Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response., PMID:40461490

Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET., PMID:40461447

Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations., PMID:40458889

Addressing SARS-CoV-2 evolution: neutralization of emerging variants of concern by the AVX/COVID-12 'Patria' vaccine based on HexaPro-S ancestral Wuhan spike or its updated BA.2.75.2 version., PMID:40458417

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603

Allostery Links hACE2 Binding, Pan-variant Neutralization and Helical Extension in the SARS-CoV-2 Spike Protein., PMID:40447075

Multiplex ACE2-RBD binding inhibition assay: An integrated tool for assessing neutralizing antibodies to SARS-CoV-2 variants and protection against breakthrough infections., PMID:40447072

Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota., PMID:40444030

ACE2, a therapeutic target of COVID-19, needs to be treated with caution., PMID:40439840

Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein., PMID:40436929

Antibody Response Against SARS-CoV-2 Spike Protein in People with HIV After COVID-19 Vaccination., PMID:40432092

Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2., PMID:40431678

Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year., PMID:40431652

The Overlooked Nucleocapsid Response: A Cohort Study of SARS-CoV-2 Vaccines in Brazil., PMID:40430765

Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies., PMID:40430736

Efficient Searches in Protein Sequence Space Through AI-Driven Iterative Learning., PMID:40429882

Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen., PMID:40429644

Development of a self-assembling multimeric Bann-RBD fusion protein in Pichia pastoris as a potential COVID-19 vaccine candidate., PMID:40425664

Is SARS-CoV-2 Spike Evolution Being Retargeted at the N-Terminal Domain?, PMID:40415355

Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant., PMID:40413500

Evaluation of broad-spectrum protection by novel mRNA vaccines against SARS-CoV-2 variants (Delta, Omicron-BA.5, XBB-EG.5) in the golden hamster model., PMID:40410742

Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains., PMID:40408899

Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster., PMID:40406109

Construction of a variable fragment (Fv)-immunoglobulin A (IgA) anti-receptor binding domain (RBD) SARS-CoV-2 library based on IgA from Indonesian COVID-19 survivors., PMID:40403817

Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles., PMID:40402246

Virus-specific antibody responses in multiple sclerosis patients treated with Ocrevus., PMID:40398376

Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination., PMID:40386778

Nanoparticle-supported, rapid, digital quantification of neutralizing antibodies against SARS-CoV-2 variants., PMID:40383030

A recombinant BCG with surface-displayed antigen induces humoral and cellular immune responses., PMID:40379714

Biophysics of SARS-CoV-2 spike protein's receptor-binding domain interaction with ACE2 and neutralizing antibodies: from computation to functional insights., PMID:40376405

Exploring Diverse Binding Mechanisms of Broadly Neutralizing Antibodies S309, S304, CYFN-1006 and VIR-7229 Targeting SARS-CoV-2 Spike Omicron Variants: Integrative Computational Modeling Reveals Balance of Evolutionary and Dynamic Adaptability in Shaping Molecular Determinants of Immune Escape., PMID:40376091

Electromagnetic waves destabilize the SARS-CoV-2 Spike protein and reduce SARS-CoV-2 Virus-Like particle (SC2-VLP) infectivity., PMID:40374718

A four-week study on the toxicity of repeated intramuscular administration of plant-based BA-CoV2-0301 vaccine against SARS-CoV-2 in Sprague-Dawley rats., PMID:40366666

Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice., PMID:40360777

SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platform., PMID:40360482

Document Download

InVivoMAb Anti-SARS-CoV-2 Spike Protein Antibody (Iv0205).pdf